A ldosterone via the activation of the mineralocorticoid receptor (MR) is a main actor of renal sodium reabsorption and water homeostasis. Extra-renal effects of the mineralocorticoid pathway have now been characterized, especially in the cardiovascular system, opening on new dimensions of the aldosterone/MR pathway in physiology, pathophysiology, and diseases. In the cardiovascular system, mineralocorticoid signaling has been shown to play an important role in the progression of cardiovascular diseases (CVDs). Previous reports using transgenic mouse models or pharmacological approaches demonstrated adverse effects of aldosterone on cardiac remodeling and fibrosis, inflammation, and hypertension.
allowing a better selection and survey of patients that could benefit from MR antagonists as a therapeutic opportunity.
We identified lipocalin 2 (Lcn2), also known as neutrophil gelatinase-associated lipocalin (NGAL) or 24p3, as a novel MR target in the cardiovascular system in mice, using a pangenomic analysis with dedicated transgenic animal models with targeted MR alteration in cardiomyocytes. 5 We showed that MR, as transcription factor, can bind directly the promoter of Lcn2 and controls its transcription. 5 Lcn2 is a 25-kDa secreted glycoprotein belonging to the lipocalin superfamily, which binds small lipophilic substances. 6 Increased systemic levels and myocardial expression of Lcn2/NGAL have been reported in several experimental models and CVDs, such as HF and atherosclerosis; it is also is considered as a biomarker of renal dysfunction because its plasma and urinary concentrations increase in kidney diseases. 7 At difference to rodents, human Lcn2/NGAL has a cysteine residue at position 87 allowing a dissulfide bond with matrix metalloproteinase 9 (MMP-9) 8 that stabilizes MMP-9, increasing its activity. 9, 10 In clinical studies, increased Lcn2/NGAL concentrations have been reported in obese patients [11] [12] [13] a population prone to develop both hyperaldosteronism and HF. [14] [15] [16] We took advantage of a previously characterized human cohort of asymptomatic obese subjects but as such prone to develop CVDs, including HF, to question whether Lcn2/ NGAL is correlated with plasma aldosterone levels and markers of extracellular matrix (ECM) remodeling. To get further insights into the role of Lcn2 as an actor of the MR signaling cascade in the cardiovascular system and its involvement in the occurrence of fibrosis, we used a genetic approach using an Lcn2 knockout mouse model that was submitted to mineralocorticoid challenge. We also tested the ability of Lcn2 to induce expression of ECM proteins in human fibroblasts.
Materials and Methods

Human Studies
A subset of 133 nonhypertensive subjects with available plasma samples, from a cohort of 140 subjects that has been previously characterized (R2C2, role of the renin-angiotensin-aldosterone system in the mechanisms of transition to HF in abdominal obesity [AO]), was studied. 17 Subjects presenting overweight (body mass index >25 kg/m 2 ) and AO (>94 cm for male and >80 cm for female) were compared with age-sex matched healthy volunteers (body mass index <25 kg/m 2 , without AO). This cohort was chosen because of its previous extensive cardiovascular phenotyping, indicating that the obese subjects display early cardiovascular abnormalities, in the absence of the confounding effects related to advanced CVDs. Study population features, cardiovascular and biological phenotyping are presented in Table S1 in the online-only Data Supplement. The study complied with the Declaration of Helsinki. Written informed consent was obtained from all subjects. Local Ethics Committee approved the study. No clinical trials.gov number was assigned to this study because it started before July 1, 2005.
Plasma aldosterone was measured using a competitive enzyme immunoassay (R&D Systems, Lille, France). Plasma measurements of galectin-3 (Gal-3; BG Medicine, Waltham, MA), free NGAL (DM9L20; R&D Systems) and NGAL/MMP-9 complexes (NGAL20; R&D Systems) were assessed using ELISA and total NGAL was computed as the sum of free and NGAL/MMP-9. Radioimmunoassay kits (Orion Diagnostica, Espoo, Finland) were used for determinations of serum collagen peptides (procollagen type I N-terminal peptide [PINP], procollagen type III N-terminal peptide [PIIINP] , and type I collagen telopeptide) as reported. 18 The same operator performed these tests, blinded for subjects group.
Mice
Four-month-old male mice constitutively inactivated for Lcn2 (Lcn2 knockout mice) were used for this study. 19 Wild-type (WT) littermates were used as control. Animals were housed in a climate-controlled facility with a 12-hour/12-hour light/dark cycle and provided free access to food and water. Experiments were approved by the Darwin ethics committee of Pierre et Marie Curie University, and conducted according to the Inserm animal care and use committee guidelines. Mice were uninephrectomized and osmotic minipumps (Charles River Laboratory, L'Arbresle, France) of aldosterone (200 μg/kg per day; Sigma-Aldrich, St-Quentin-Fallavier, France) were implanted subcutaneously. 20 The day after surgery, the drinking water was replaced with 1% saline. Mice were on normal chow. In sham-treated animals, the kidney was exposed but not removed. Four weeks later, mice were euthanized by decapitation. Systolic blood pressure was measured by tail cuff plethysmography in trained conscious mice. Ten measurements per mice were taken every day between 10 am and 12 am during 5 days using a BP2000 Visitech model (Bioseb, Vitrolles, France) as described previously.
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Culture of Human Cardiac Fibroblasts
Human cardiac fibroblasts (Promocell, Heidelberg, Germany) were cultured in the medium fibroblasts media 3 (Promocell) according to the manufacturer's instructions. human cardiac fibroblasts were used between passages 5 to 7. Cells were incubated for 24 hours with different concentrations of recombinant NGAL (5, 50, and 500 ng/mL; R&D Systems).
Statistics
All analyses were performed using GraphPad Prism V6.01 (GraphPad Software, San Diego, CA) or SAS R9.3 (SAS Institute, Cary, NC) softwares. The two-tailed significance level was set to P<0.05. Results were expressed as mean±SEM, median (interquartile range) or correlation 
Results
Lcn2/NGAL is Related to Cardiovascular Remodeling in Humans
In a cohort of normotensive asymptomatic obese subjects and age-sex matched healthy volunteers, 17 plasma-free NGAL and Gal-3 concentrations did not significantly differ between the 2 populations, whereas subjects with AO displayed a 3.8-fold higher NGAL/MMP-9 concentration (P<0.0001), 1.4-fold in plasma aldosterone levels (P<0.0001), 1.9-fold higher in PINP (P<0.0001), 4.1-fold higher in cardiotrophin-1 (CT-1) (P<0.0001), and 20% lower in type I collagen telopeptide concentration (P<0.0001) versus controls (Table 1) . No significant correlation was observed between free NGAL and plasma aldosterone, or with ECM biomarkers (data not shown). In contrast, in the whole study population, plasma NGAL/MMP-9 complexes were found positively correlated with plasma aldosterone ( Figure 1A ; Table 2 ). NGAL/MMP-9 complexes were also positively correlated with PINP (r s =0.49; P<0.0001), PIIINP (r s =0.23; P=0.01; Figure 1B and 1C; Table 2 ; Fig. S1 ) and negatively correlated with type I collagen telopeptide (r s =−0.38; P<0.0001; Figure 1D ; Table 2 ). In healthy subjects, none of the parameters are correlated together (Table 2 ). In the subjects with AO, NGAL/MMP-9 was significantly correlated with plasma PINP, PIIINP, and type I collagen telopeptide (Table 2) .
Lcn2 Gene Inactivation Limits the Vascular Fibrosis Induced by NAS Challenge in Mice
To progress in the understanding of the role of Lcn2, we characterized its involvement in the fibrotic phenotype induced by (Table 3) . NAS challenge induced cardiac and renal hypertrophy in both genotypes as shown by the augmentation of cardiac weight/tibia length and renal weight/tibia length ratios (Table 3) . WT mice submitted to the NAS challenge developed an increase in systolic blood pressure (Table 3 ). Of note, the increase in blood pressure elicited by NAS was reduced in mice with Lcn2 inactivation, compared with that of WT mice (Table 3) .
NAS challenge in WT mice decreased the aortic vasodilatory response to acetylcholine (endothelium-dependent vasorelaxation; Figure 2A ; Table S2 ) and sodium nitroprusside Table  S2 ) and increased the vasoconstrictive response to phenylephrine (a vasoconstrictor α-adrenergic agonist) as previously reported ( Figure 2C ; Table S2 ). 22 Gene inactivation of Lcn2 did not affect vascular response to these agents ( Figure 2A ; Table S2 ) as previously reported. 23 Therefore, NAS treatment modified the contractile phenotype regardless the Lcn2 genotype because Lcn2 inactivation had no effect on NAS-induced alterations in vascular response. NAS-induced increased protein carbonylation related to oxidative stress and osteopontin expression in aorta of WT mice but not of Lcn2 knockout mice ( Figure 3A and 3B) .
NAS treatment induced fibrosis in the coronary vessels in WT mice, an effect that was not observed in Lcn2 knockout mice ( Figure 4A and 4B). Consistent with this observation, collagen I/collagen III protein ratio was increased in the heart from WT mice under NAS treatment, but not altered in NAStreated Lcn2 knockout mice ( Figure 4C ). Cardiac expression of Gal-3 and CT-1 was not modified by NAS ( Figure S2 ). Fibrosis ( Figure 4D and 4E) also occurred in the aorta of WT, not Lcn2 knockout mice, after NAS challenge, with parallel changes in collagen I expression ( Figure 4F ). Thus, loss of Lcn2 prevented the induction of a profibrotic perivascular phenotype.
Lcn2 Gene Inactivation Blunted the Increased in a Plasma Biomarker of ECM Remodeling Induced by NAS Challenge in Mice
Because loss of Lcn2 prevented ECM remodeling in cardiovascular tissues after NAS challenge in mice, we next analyzed a circulating biomarker to evaluate the profibrotic status of the mice treated or not with NAS. In the plasma of WT mice submitted to NAS treatment, PINP (a marker of collagen type I synthesis) was increased by 50%, as compared with shamoperated mice ( Figure 5A ). The absence of Lcn2 blunted the PINP production induced by NAS ( Figure 5A ). The plasma levels of CT-1 and Gal-3, 2 profibrotic molecules previously reported to be involved in the aldosterone-induced ECM remodeling in the cardiovascular system 24, 25 were analyzed. CT-1 plasma level was not detectable. Gal-3 plasma level was increased by the NAS challenge, an effect blunted in Lcn2 knockout mice ( Figure 5B ).
Lcn2 Induces a Fibrotic Phenotype in Cultured Fibroblasts
In mice, Lcn2 is an aldosterone target in cardiomyocytes, endothelium, and vascular smooth muscle cells. 5 Lcn2 is a secreted protein and can act as autocrine and paracrine agent. We, therefore, analyzed whether recombinant NGAL could be a direct modulator of profibrotic genes in vascular smooth muscle cells and fibroblasts that play a key role in cardiovascular remodeling. NGAL has no effect on collagen type I expression in vascular smooth muscle cells ( Figure S3 ). In human fibroblasts, recombinant human NGAL application for 24 hours induced a dose-dependent increase in collagen type I protein expression ( Figure 6A ) but not in fibronectin ( Figure 6B ). Moreover, recombinant NGAL increased the expression of Gal-3 ( Figure 6C ) and CT-1 ( Figure 6D ), as well as secretion of Gal-3 and CT-1 in the medium ( Figure 6E and 6F).
Discussion
Upregulation of Lcn2 expression has been described in several pathological conditions, such as obesity, inflammation, and cancer 8 and more recently in the cardiovascular system. [26] [27] [28] [29] Moreover, elevated circulating NGAL concentrations predict adverse cardiovascular events in patients. 29, 30 We and others, have previously showed that Lcn2/NGAL is a direct target gene of the aldosterone/MR signaling pathway in the cardiovascular system. 5, 31, 32 The aim of this study was to analyze whether Lcn2/NGAL is a key actor of mineralocorticoid action in the cardiovascular system. We analyzed 2 conditions associated with increased aldosterone/MR activation (AO in human subjects and NAS challenge in a mouse model with Lcn2 gene deletion) and provide mechanistic insights in the profibrotic effects of Lcn2/NGAL.
We showed a positive correlation between NGAL/MMP-9 complex plasma levels and aldosteronemia in human subjects. This was mainly driven by AO. To our knowledge, this is the first evidence of a possible link between NGAL and the mineralocorticoid signaling pathway in human. To unravel the possible contribution of Lcn2/NGAL in the pathophysiological effects of MR activation in the cardiovascular system, we used a genetic approach and showed that constitutive deletion of Lcn2 in mice prevented (1) the increase of blood pressure and (2) cardiovascular ECM remodeling induced by a mineralocorticoid challenge.
Two clinical studies reported a link between NGAL and blood pressure. Polymorphisms in the human NGAL promoter correlated with blood pressure levels in a populationbased prospective cohort study of cardiovascular risk factors in a general population of Hong Kong. 33 However, correlation between NGAL plasma levels, which may be affected by these polymorphisms and blood pressure was not studied. 33 Another study reported that patients with essential hypertension had higher NGAL plasma levels than normotensive patients, and that plasma NGAL was significantly correlated with systolic blood pressure levels. 34 We cannot explain why loss of Lcn2 prevents blood pressure increase induced by a mineralocorticoid challenge. Renal sodium handling and vascular reactivity are similar in WT and Lcn2 knockout mice. We noticed, however, that vascular oxidative stress is blunted. Further studies are required to explore whether oxidative stress is part of the benefits of Lcn2 inactivation on blood pressure. Because the increase in blood pressure by the aldosterone-salt challenge is blunted in Lcn2 knockout mice, we cannot exclude a consequence of lower blood pressure on reduced vascular remodeling. The role of Lcn2 on the interplay between blood pressure and ECM remodeling, therefore, affecting arterial stiffness is, however, difficult to assess because both the parameters influence each other. We provide evidences that Lcn2 and perivascular fibrosis are linked: loss of Lcn2 prevents the increase in cardiac and aortic collagen I, as well as ECM remodeling assessed by collagen fibers deposition into aorta. Interestingly, loss of Lcn2 also blunts the increase in plasma PINP, a marker of procollagen type I processing in mice challenged by mineralocorticoids. This preclinical observation extends to humans: within a cross-sectional study of asymptomatic normotensive obese participants at risk to develop cardiovascular disease but without left ventricular hypertrophy (ie, HF stage A), 17 we observed that plasma NGAL/ MMP-9 was significantly associated with fibrosis biomarkers previously associated with mineralocorticoid effects in HF. 18 This suggests that NGAL/MMP-9 is already altered at the early stage of cardiac remodeling that precedes clinical HF, and may, therefore, be a key factor in the aldosterone signaling pathway leading to tissue remodeling. This is further strengthened by cellular data using human cardiac fibroblast where we unveiled a direct profibrotic effect of recombinant human NGAL via increased collagen I production and the synthesis and secretion of the profibrotic molecules, such as Gal-3 and CT-1.
This study has several limitations. Because of the lack of a specific cysteine residue, Lcn2/MMP-9 complex is not present in rodents opposed to humans. Therefore, we cannot assess the potential role of the interaction between Lcn2 and MMP-9 in the beneficial effects we observed in the mouse model. A second limitation is the use of a global Lcn2 knockout. This model does not allow us to identify the cell type(s) involved in the observed effects in Lcn2 knockout mice. We cannot rule out that Lcn2 has other targets than fibroblasts in vivo. Moreover, because Lcn2 is a secreted protein, it may act at distance from its origin of synthesis.
In conclusion, Lcn2 seems as a novel actor in the pathological activation of the cardiovascular mineralocorticoid cascade, mandatory for the elevation of blood pressure and vascular fibrosis. This study demonstrates that Lcn2/NGAL is a key element in the signaling events modulated by mineralocorticoid challenge, in relation with blood pressure increase and ECM remodeling. Whether Lcn2/NGAL may represent a novel therapeutic target in ECM remodeling is an exciting perspective.
Perspectives
We demonstrate in this study that Lcn2 plays a key role in the increased blood pressure and remodeling process induced by mineralocorticoid excess, therefore, representing a potential biotarget for pharmacological modulation of the mineralocorticoid system. The rise of NGAL/MMP-9 and its association with plasma aldosterone levels and fibrosis biomarkers in subjects with stage A HF suggest that it may also serve as a biomarker of excessive MR activation, and help identifying populations more prone to respond to mineralocorticoid receptor antagonists prescribed to prevent adverse cardiovascular remodeling.
SUPPLEMENTAL METHODS
Tissue sampling
Hearts were rinsed in cold PBS (Phosphate Buffer Solution), weighted and cut into 3 parts (transversal cut). The base and the apex were used for biochemical studies, the mid-part for morphological studies. Aortas were rinsed in cold PBS. Thoracic aorta was used to assess vascular reactivity; a small piece was used for morphological studies. Abdominal aorta was used for biochemical studies. Left tibia length was used for organ weight normalization.
Vascular Reactivity Analysis
Vascular contractile and relaxing responses were assessed in isolated thoracic aortas as described.
1 Aortic rings were maximally contracted with isotonic potassium chloride solution (KCl, 80mM) and then contractile capacity of each ring was measured with a submaximal concentration of phenylephrine (Phe, 10 -5 M). The contraction evoked by Phe (10 -9 to 10 -5 M) tested the α-adrenergic pathway. The dose response to acetylcholine (Ach, 10 -9 to 10 -6 ) was determined in rings precontracted by 10 -5 M Phe to evaluate endothelium dependent relaxation. Dose-response to the NO donor sodium nitroprusside (SNP, 10 -9 to 10 -4 M) was used to measure vascular smooth muscle cell (VSMC) sensitivity to nitric oxide (NO) pathway. All the chemicals were purchase from Sigma-Aldrich if not specified otherwise. pEC50 were calculated using a non-linear regression with three parameters (GraphPad Prism V.6.01, San Diego, USA).
Circulating marker aminoterminal propeptide of type I collagen (PINP) in mice
Blood was collected during sacrifice using Microvette® capillary tube coated with lithium heparin (Sarstedt, Marnay, France). Plasma was retrieved after 5 minutes centrifugation (2000g, room temperature). PINP concentrations were measured by ELISA according to the manufacturer's instructions (R&D Systems).
Histological procedures
Sirius red staining to show collagen content was performed on 5 μm sections of thoracic aortas and mid-part the heart fixed with 4% paraformaldehyde for 24 hours and embedded in paraffin. Image acquisition was made using a Leica DM4000B microscope and Leica Application Suite software (Leica Microsystems, Nanterre, France). Collagen content was quantified by surface of Sirius red staining over vessel surface using ImageJ software, and expressed as percentage of the total cross-sectional area.
Culture of vascular smooth muscle cells
Rat A7R5 cell line (ATCC, Molsheim, France) and vascular smooth muscle cell primary culture were cultured in Dulbecco's Modified Eagle Medium (Life Technologies, Saint Aubin, France) according to the manufacturer´s instructions. Cells were used between passages 5-7. Cells were incubated for 24 hours with different concentrations of recombinant NGAL (5, 10, 50, 100, 500 ng/ml, R&D Systems).
cDNA isolation and Real-Time PCR
Total RNA from cells were extracted using the TRIZOL® reagent (Life Technologies , Saint Aubin, France), according to manufacturer protocol. Reverse transcription of mRNA (500ng) was performed using Superscript II Reverse Transcriptase KIT (Life Technologies). Transcript levels of genes were analyzed by real-time PCR (fluorescence detection of SYBR Green) in an iCycler iQ (Bio-Rad, Cergy-St-Christophe, France). For each sample, mRNA levels were normalized to the housekeeping gene 18S.
Western Blotting
Western blot analyses were performed in aorta and heart from WT and Lcn2 KO mice and in human cardiac fibroblasts. Cell and tissue samples were homogenized using a Roche cOmplete lysis-M buffer with protease inhibitors and phosphatases inhibitors cocktail (Roche, Neuilly, France). Extracts were centrifuged at 14000 rpm for 10 minutes at 4°C and protein concentration in the supernatant was determined by the Pierce protein assay (Bio-Rad). Thirty micrograms of total proteins were loaded on 4-15% polyacrylamide gel and transferred to nitrocellulose membranes (Bio-Rad). Membranes were incubated with primary antibodies for: Collagen type I (Abcam, Cambridge, UK, dilution 1:1000 for tissues or Santa Cruz Biotechnology, Heidleberg, Germany, dilution 1:250 for cell samples), Collagen type 3 (Santa Cruz Biotechnology, dilution 1:250), Elastin (Abcam, dilution 1:250), Fibronectin (Millipore, St-Quentin-en-Yvelines, France, dilution 1:250), Galectin-3 (Santa Cruz Biotechnology, dilution 1:1000), Cardiotrophin-1 (Abcam, dilution 1:500) and β-actin (Sigma-Aldrich, dilution 1:1000) as a loading control. After washing, detection was made through incubation with peroxidase-conjugated secondary antibody, and developed using an ECL chemiluminescence kit (Bio-Rad). After densitometric analyses, optical density values were expressed as arbitrary units. Results are expressed as fold increase over the values of the control group. Western Blots were performed at least in triplicate for each experimental condition.
ELISA
Galectin-3 and Cardiotrophin-1 levels in the supernatant of human cardiac fibroblasts and mice cardiac tissue were measured using ELISA (R&D Systems). ELISA were performed according the manufacter´s instructions. 
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